Bayer (FRA:BAYN) Given a €70.00 Price Target at Deutsche Bank

Deutsche Bank set a €70.00 ($81.40) price objective on Bayer (FRA:BAYN) in a research report sent to investors on Friday, Borsen Zeitung reports. The brokerage currently has a neutral rating on the healthcare company’s stock.

Several other research firms have also weighed in on BAYN. HSBC set a €63.00 ($73.26) target price on shares of Bayer and gave the stock a neutral rating in a report on Wednesday, August 7th. Goldman Sachs Group set a €77.00 ($89.53) target price on shares of Bayer and gave the stock a buy rating in a report on Monday, August 5th. JPMorgan Chase & Co. set a €69.00 ($80.23) target price on shares of Bayer and gave the stock a neutral rating in a report on Monday, August 5th. Nord/LB set a €56.00 ($65.12) target price on shares of Bayer and gave the stock a neutral rating in a report on Tuesday, July 30th. Finally, Baader Bank set a €123.00 ($143.02) price target on shares of Bayer and gave the stock a buy rating in a research report on Wednesday, August 7th. One investment analyst has rated the stock with a sell rating, eleven have assigned a hold rating and twelve have given a buy rating to the stock. The stock presently has an average rating of Hold and an average target price of €80.57 ($93.68).

BAYN opened at €63.76 ($74.14) on Friday. The stock has a 50-day moving average price of €58.89. Bayer has a twelve month low of €91.58 ($106.49) and a twelve month high of €123.82 ($143.98).

Bayer Company Profile

Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, Crop Science, and Animal Health segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.

Read More: Holder of Record

Analyst Recommendations for Bayer (FRA:BAYN)

Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.